MSP 2020
Alternative Names: MSP-2020Latest Information Update: 26 Aug 2026
At a glance
- Originator Mindset Pharma
- Developer Otsuka America Pharmaceutical
- Class Indoles; Neuropsychotherapeutics; Pyrrolidines; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Major depressive disorder
Most Recent Events
- 17 Jul 2026 Otsuka America Pharmaceutical terminates a phase I trial in Major depressive disorder in United Kingdom due to operational and scientific constraints and termination was not based on safety concerns (NCT07329621)
- 15 Jan 2026 Phase-I clinical trials in Major depressive disorder (In volunteers) in United Kingdom (PO) (NCT07329621)
- 05 Jan 2026 Otsuka America Pharmaceutical plans a phase I trial for Major depressive disorder (In volunteers) in United Kingdom (PO) (NCT07329621)